Category Archives: Stem Cell Research

Public release date: 9-Oct-2013 [ | E-mail | Share ] Contact: Kara Gavin kegavin@umich.edu 734-764-2220 University of Michigan Health System ANN ARBOR, Mich. Two patients with amyotrophic lateral sclerosis (ALS) have received stem cell injections to their spinal cords at the University of Michigan Health System the first two to receive the experimental injections in Michigan as part of a national clinical trial. Both research volunteers have returned home and will receive follow-up monitoring and testing to help U-M researchers assess the safety and any potential effect of the injections. Additional patients with the condition, also known as Lou Gehrig's disease, are being evaluated for possible participation in the trial at U-M and Emory University. The Phase II trial is approved by the U.S. Food and Drug Administration and funded by Neuralstem, Inc., the Maryland-based company whose stem-cell product the trial is testing. It seeks to study any effect that injected stem cells might have on motor neurons muscle-controlling nerve cells that die in ALS patients, eventually robbing them of the ability to walk, speak and breathe. Eva L. Feldman, M.D., Ph.D., the Russell N. DeJong professor of neurology at the U-M Medical School and director of the A. Alfred … Continue reading →

Newswise ANN ARBOR, Mich. Two patients with amyotrophic lateral sclerosis (ALS) have received stem cell injections to their spinal cords at the University of Michigan Health System the first two to receive the experimental injections in Michigan as part of a national clinical trial. Both research volunteers have returned home and will receive follow-up monitoring and testing to help U-M researchers assess the safety and any potential effect of the injections. Additional patients with the condition, also known as Lou Gehrigs disease, are being evaluated for possible participation in the trial at U-M and Emory University. The Phase II trial is approved by the U.S. Food and Drug Administration and funded by Neuralstem, Inc., the Maryland-based company whose stem-cell product the trial is testing. It seeks to study any effect that injected stem cells might have on motor neurons muscle-controlling nerve cells that die in ALS patients, eventually robbing them of the ability to walk, speak and breathe. Eva L. Feldman, M.D., Ph.D., the Russell N. DeJong professor of neurology at the U-M Medical School and director of the A. Alfred Taubman Medical Research Institute, is the principal investigator for the trial. Feldman serves as an unpaid consultant to the … Continue reading →

NEWARK, Calif., Oct. 9, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (STEM), the leading stem cell company developing novel cell-based therapeutics for disorders of the central nervous system, announced today that President and CEO Martin McGlynn will make a presentation on the Company's programs and operations at the Regen Med Partnering Forum during the 2013 Stem Cell Meeting on the Mesa, to be held October 14-16. Mr. McGlynn is scheduled to speak at 11:00 a.m. Pacific Time on Monday, October 14, at the Estancia La Jolla Hotel in La Jolla, Calif. A live video webcast of all company presentations will be available at: http://stemcellmeetingonthemesa.com/webcast/ and will also be published on the Alliance for Regenerative Medicine's (ARM) website shortly after the event. The Stem Cell Meeting on the Mesa is a three-day conference organized by the Sanford Consortium for Regenerative Medicine, the California Institute for Regenerative Medicine (CIRM), and ARM. The conference brings together senior members of the regenerative medicine industry with the scientific research community to advance stem cell science into cures. The first two days of the conference, October 14-15, features the Regen Med Partnering Forum, the only partnering meeting organized specifically for the regenerative medicine and advanced therapies industry. … Continue reading →

What is Happening with Stem Cell Research What is Happening with Stem Cell Research. By: msworldinc … Continue reading →

SAN DIEGO--(BUSINESS WIRE)-- Cytori Therapeutics, Inc. (CYTX) will give a company presentation at the 3rd Annual Regen Med Partnering Forum, part of the 2013 Stem Cell Meeting on the Mesa on Tuesday, October 15. In addition, Cytoris CEO Chris Calhoun will be participating on a conference panel on Monday, October 14. The following are specific details regarding Cytoris presentation and panel participation at the conference: Panel III: Financing Regenerative Medicine & Advanced Therapies Cytori Therapeutics, Inc. Company Presentation Both the presentation and the panel will be available live and will be available on the Webcasts page of Cytoris investor relations site approximately two weeks following the conference. The 2013 Stem Cell Meeting on the Mesa conference is being organized by the Alliance for Regenerative Medicine (ARM), the California Institute for Regenerative Medicine and the Sanford Consortium for Regenerative Medicine with the intention of bringing together senior members of the regenerative medicine industry with the scientific research community to advance stem cell science into cures. About Cytori Cytori Therapeutics is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and other medical conditions. Our scientific data suggest ADRCs improve blood flow, moderate the inflammatory response and … Continue reading →

A German government-funded research project is using laser tomography to help scale-up stem cell production for anticipated new therapies. Work on the Ministry of Education and Research (BMBF)-backed Ultrasensitive Verification and Manipulation of Cells and/or Tissue and their molecular Substances started in July and will receive 4.1million over the course of three years. Central to the project is a technique known as scanning laser optical tomography (SLOT), developed and patented by Laser Zentrum Hannover, while other project partners with optics expertise include the advanced microscopy specialist LaVision BioTec and lens maker Sill Optics. The SLOT technique is used to monitor cell cultures consisting of so-called pluripotent stem cells (hPSC). Once isolated from an embryo, these cells have the ability to turn into virtually any cell type. In the new TOMOSphere project, SLOT will, for the first time, be used to monitor quantitatively the absolute number of cells in cultured, endogenous groups. The results are expected improve understanding of the physiology of hPSC and other stem cells, as well continuous control of their characteristics. Light combination LZH scientists have previously used SLOT to generate optical images similar to those produced by a familiar X-ray computed tomography (CT) scanner. Having already created … Continue reading →

RICHMOND, Calif., Oct. 7, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (SGMO) announced today that Elizabeth Wolffe, Ph.D., Sangamo's senior director of corporate communications, will give a company presentation at the 3rd Annual Regen Med Partnering Forum, part of the Stem Cell Meeting on the Mesa to be held October 14-16, 2013, in La Jolla, CA. (Logo: http://photos.prnewswire.com/prnh/20130102/SF35903LOGO) Organized by the Alliance for Regenerative Medicine (ARM), the California Institute for Regenerative Medicine (CIRM) and the Sanford Consortium for Regenerative Medicine, the 2013 Stem Cell Meeting on the Mesa is a three-day conference aimed at bringing together members of the regenerative medicine industry with the scientific research community to advance stem cell science into cures. The Regen Med Partnering Forum, held October 14 &15 at the Estancia La Jolla Hotel, is the only partnering meeting organized specifically for the regenerative medicine and advanced therapies industry. The following are specific details regarding Sangamo's presentation at the conference: Event: Regen Med Partnering Forum 2013 Stem Cell Meeting on the Mesa Date: October 14, 2013 Time: 5:15 p.m. Location: Estancia La Jolla Hotel & Spa, 9700 North Torrey Pines Road, La Jolla, CA 92037 A live video webcast of all company presentations will be available … Continue reading →

NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)-- BrainStorm Cell Therapeutics (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it is presenting at multiple scientific conferences this month. Israel Stem Cell Society 5thInternational Stem Cell Meeting Professor Dani Offen, BrainStorms Chief Scientific Advisor, will present at the 5th International Stem Cell Meeting sponsored by the Israel Stem Cell Society, October 8th-9th in Jerusalem. Prof. Offen will be making a poster presentation on October 8th at 17:30, and an oral presentation on Oct 9th at 17:15. Israel Braintech 2013 Professor Dani Offen, BrainStorms Chief Scientific Advisor, will present at the Israel Braintech 2013 Meeting, October 14th-15th in Tel Aviv. The meeting is sponsored by Israel Brain Technologies (IBT), a non-profit organization inspired by the vision of Israeli President Shimon Peres to promote Israels neurotechnology innovation hub. Prof. Offens oral presentation will be part of the session entitled: A Spotlight on the Israeli NeuroTech Industry, October 15th at 12:15. Israel A.L.S Research Association Professor Dimitrios Karussis, Principal Investigator of BrainStorms clinical trials at Jerusalems Hadassah Medical Center, will present at the Israel A.L.S Research Association (IsrA.L.S) Conference, From the Lab to the Clinic: An Overview of … Continue reading →

NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)-- BrainStorm Cell Therapeutics (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Dr. Adrian Harel, Director R&D, will present at the 3rd Annual Regen Med Partnering Forum, part of the Stem Cell Meeting on the Mesa to be held October 14-16 in La Jolla, CA. Organized by the Alliance for Regenerative Medicine (ARM), the California Institute for Regenerative Medicine (CIRM) and the Sanford Consortium for Regenerative Medicine, the 2013 Stem Cell Meeting on the Mesa is a three-day conference aimed at bringing together senior members of the regenerative medicine industry with the scientific research community to advance stem cell science into cures. The Regen Med Partnering Forum, held October 14 & 15 at the Estancia La Jolla Hotel, is the only partnering meeting organized specifically for the regenerative medicine and advanced therapies industry. The meeting also features a nationally recognized Scientific Symposium, held October 16 at the Salk Institute for Biological Studies, showcasing leading academic research in the field of regenerative medicine. Combined, these meetings attract over 800 attendees from around the globe, fostering key partnerships through one-on-one meetings while also highlighting clinical and commercial progress in … Continue reading →

07.10.2013 - (idw) Laser Zentrum Hannover e.V. The Laser Zentrum Hannover (LZH e.V.) is currently active in a project dealing with the tomographic monitoring of 3-D cell cultures consisting of pluripotent stem cells (hPSC). The Laser Zentrum Hannover (LZH e.V.) is currently active in a project dealing with the tomographic monitoring of 3-D cell cultures consisting of pluripotent stem cells (hPSC). The goal of the collaborative research project is, for the first time, to use Scanning Laser Optical Tomography (SLOT) for non-invasive, direct, quantitative compilation of the absolute number of cells in cultured, endogenous cell groups. The results of the project TOMOSphere should bring a better understanding of the physiology of hPSC and other stem cells, as well as a continuous control of their characteristics, making decisive progress in therapeutic concepts possible. For the investigations, SLOT-technology, which was developed and patented at the LZH, was used for the first time for the temporally and spatially resolved observation of native or fixed cells in three-dimensional aggregate structures. Knowledge gained from using this process can be used to classify and later to sort the aggregates, for example concerning heterogeneity of the cell structure, possible cyst formation, or the deposition of extracellular matrixes. … Continue reading →